Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 02 Jul 2019 Status changed from not yet recruiting to recruiting.
- 18 Mar 2019 Planned End Date changed from 2 Mar 2021 to 29 Mar 2021.
- 18 Mar 2019 Planned primary completion date changed from 1 Mar 2020 to 26 Mar 2020.